XERS XERIS BIOPHARMA HOLDINGS
Health Care · Russell 2000
Next earnings: not announced yet
What 8 analyst firms say about XERIS BIOPHARMA HOLDINGS: their latest ratings, price targets and how far the stock is from them. How it works
Analyst window: Latest analyst report within last 1 year
Analyst view · last 1Y
8 rated views · 8 analyst/firm records · 8 firms
Radar score
- Russell 2000 · Top Picks · 6MNot scored · Average target is not above the current price
- Russell 2000 · Safest consensus · 6MNot scored · Average target is not above the current price
Recent analyst activity · last 90 days
Our tracked history has 4 reports on XERS from 3 analyst firms in the last 90 days (8 firms in the past year).
Comparing each firm's latest target with its previous one: 1 raised its price target and 2 have their first observed target in the past year.
No firm's latest available rating differs from its previous one.
Latest observed target change: Barclays raised its target from $9.00 (set 9 Dec 2025) to $14.00 on 6 Oct 2026.
Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.
| Firm | Analyst | Latest rating | Report date | Latest target (USD) |
|---|---|---|---|---|
| Barclays | Glen Santangelo | Buy | 20 Aug 2026 | Conflicting reports · excluded |
| Craig-Hallum | Chase Knickerbocker | Buy | 8 Jul 2026 | 12.00 USD |
| H.C. Wainwright | Brandon Folkes | Buy | 7 Aug 2026 | 10.00 USD |
| Jefferies | Dennis Ding | Buy | 6 Oct 2026 | 12.00 USD |
| Leerink Partners | Roanna Ruiz | Buy | 10 Sep 2026 | 16.00 USD |
| Oppenheimer | Unnamed analyst | Buy | 7 Nov 2025 | 18.00 USD |
| Piper Sandler | David Amsellem | Hold | 6 Aug 2026 | 8.00 USD |
| Data feed RESEARCH | Research Team | Hold | 15 Jun 2026 | — |
Partial coverage · checked 6 Nov (6 Nov 2026, 06:00 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.